Silverback Therapeutics raises $37.5M from OrbiMed, Celgene and Alexandria; Series A totals $47.5M as it unveils disease‑site targeting platform

Silverback Therapeutics revealed its technology that delivers systemically administered therapies which activate only at disease sites and announced an additional $37.5 million, bringing its Series A to $47.5 million from investors including OrbiMed, Celgene, and Alexandria.

No comments yet.